[Psoriasis updates].
Service de Dermatologie, Hôpital La Grave, Toulouse, France. serge@boulinguez.com.fr
S
S
Boulinguez
D000068879:Adalimumab; D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D015535:Arthritis, Psoriatic / Q000188:drug therapy / Q000453:epidemiology; D001691:Biological Therapy / Q000009:adverse effects; D002986:Clinical Trials as Topic; D015897:Comorbidity; D003879:Dermatologic Agents / Q000627:therapeutic use; D004643:Emollients; D000068800:Etanercept; D005260:Female; D006203:Hair Preparations; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D008297:Male; D011565:Psoriasis / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology; D011788:Quality of Life; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D012720:Severity of Illness Index; D000069549:Ustekinumab; D055815:Young Adult
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D004643:Emollients; D006203:Hair Preparations; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept